Equita raises DiaSorin target to EUR 90: DiaSorin stock gains 2.60 percent

Published on 10/21/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was EUR 315.00 million, up 2.90 percent year over year. DiaSorin stock costs EUR 81.57 on October 21, 2026, 2.60 percent above the Xetra close.

Analyst upgrade and earnings

Equita moved its DiaSorin rating to Buy and raised the target to EUR 90.00 on October 21, 2026.
Second-quarter revenue was EUR 315.00 million, 2.90 percent higher year over year.
DiaSorin stock trades at EUR 81.57 at 11:07 a.m. CEST at Lang & Schwarz on October 21, 2026, 2.60 percent above the Xetra close of October 20, 2026.

DiaSorin, IT0003492391, Illustration mit AI erstellt.

DiaSorin stock trades at EUR 81.57 at Lang & Schwarz on October 21, 2026, at 11:07 a.m. CEST, up 2.60 percent versus the Xetra close of October 20, 2026 at EUR 79.50. The immediate catalyst is an Equita upgrade: as Milano Finanza reported on October 21, 2026, the house raised its target from EUR 72.00 to EUR 90.00 and changed its rating from Hold to Buy.

Equita sees faster growth

Equita expects third-quarter revenue of EUR 308.00 million, an increase of 10.20 percent from the third quarter of 2025, with organic growth of 7.60 percent. Its adjusted EBITDA estimate is EUR 99.00 million, up 12.50 percent, implying a 32.10 percent margin. The figures and target change were reported by Milano Finanza on October 21, 2026.

The comparison with the latest reported quarter is also constructive. DiaSorin generated EUR 315.00 million of revenue in the second quarter of 2026, 2.90 percent above the second quarter of 2025, according to Milano Finanza. Equita also expects full-year 2026 revenue of EUR 1.25 billion, up 4.60 percent, while its adjusted EBITDA margin estimate is 32.50 percent.

What does the target imply?

Equita's EUR 90.00 target is 10.33 percent above the Lang & Schwarz price of EUR 81.57. That gap gives the upgrade a measurable valuation angle, while the upcoming results must show whether the projected second-half acceleration is emerging in reported revenue and profitability.

Three dated company developments

On October 7, 2026, MarketScreener reported that DiaSorin completed its EUR 250.00 million buyback program after acquiring 3.80 million shares. On October 13, 2026, DiaSorin announced FDA approval for two automated Parvovirus B19 tests.

On October 21, 2026, Equita raised its target to EUR 90.00 and moved the rating to Buy, according to Milano Finanza. The sequence links capital allocation, product expansion and the earnings outlook without relying on a single operating metric.

Next reporting date

The next scheduled event is DiaSorin's third-quarter 2026 results approval on November 12, 2026, with the investor conference call planned for the same date, according to FinancialFilings.

Stock after the upgrade

DiaSorin's market capitalization is EUR 4.0 billion, and its 52-week range is EUR 52.34 to EUR 82.30 as of October 21, 2026. The stock therefore sits EUR 0.73 below its 52-week high, while the Equita target is EUR 8.43 above the Lang & Schwarz price. The company is listed on Euronext Milan and operates in medical diagnostics and research.

DiaSorin was trading at EUR 81.57 at Lang & Schwarz on October 21, 2026, at 11:07 a.m. CEST, up 2.60 percent versus the Xetra close of October 20, 2026 at EUR 79.50. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.